COVID-19 Resource Center
COVID-19 Resource Center
October 08, 2020
1 min read
Save

Baricitinib plus remdesivir improve outcomes for patients with COVID-19 vs. remdesivir alone

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients with COVID-19 who were treated with baricitinib and remdesivir had a lower median time to hospital discharge and lower mortality rates than patients treated with remdesivir alone, Eli Lilly & Co. and Incyte announced in a press release.

John Beigel, MD, associate director for clinical research in the National Institute of Allergy and Infectious Diseases’ division of microbiology and infectious diseases, presented the new findings from the Adaptive COVID-19 Treatment Trial (ACTT-2) at the International Society for Influenza and other Respiratory Virus Diseases Antiviral Group’s virtual Therapeutics for COVID-19 conference.

Doctor Holding Test Tube That Reads COVID-19

The ACTT-2 trial found the combination of baricitinib and remdesivir reduced time to hospital discharge from 8 days to 7 days, improved odds of clinical status improvement at day 15 by 30% and fewer deaths at day 29 compared with remdesivir alone. Photo Source: Adobe Stock

New efficacy and safety data from the ACTT-2 showed that fewer patients treated with baricitinib (Olumiant, Eli Lilly & Co.) and remdesivir (Gilead Sciences Inc.) died (5.1% vs. 7.8%; HR = 0.65; 95% CI, 1.08) compared with remdesivir alone. Patients who required supplemental oxygen (60% lower) or high-flow oxygen/non-invasive ventilation (43% lower) saw the most significant reductions in mortality.

According to the release, the ACTT-2 also found the combination of baricitinib and remdesivir reduced time to hospital discharge from 8 days to 7 days (IR = 1.16; 95% CI, 1.01-1.32), improved odds of clinical status improvement at day 15 by 30% (OR = 1.3; 95% CI, 1.0-1.6) and fewer deaths at day 29 (5.1% vs. 7.8%; HR=0.65; 95% CI, 0.39-1.08) compared with remdesivir alone.

“We are excited that these results add to the potential role for baricitinib to treat hospitalized COVID-19 patients,” Ilya Yuffa, senior vice president of Eli Lilly and president of Lilly Bio-Medicines. “Lilly is committed to identifying impactful preventions and treatments, and we are engaged in discussions with the FDA regarding the potential to make baricitinib available to hospitalized patients as quickly as possible.”

Eli Lilly said in the release that it is “continuing conversations” with the FDA regarding an emergency use authorization to treat COVID-19 with baricitinib. Baricitinib’s efficacy and safety in treating COVID-19 has not been established, per the release.